About TrialCompass
A clearer path through clinical trials for rare cancers — starting with T-cell lymphoma.
What is TrialCompass?
TrialCompass is a free, expert-curated clinical trial navigation tool built to close a gap rare-cancer patients face every day: the difficulty of finding and understanding trials that may matter for their situation. Common cancers have dedicated matching resources; rare cancers like T-cell lymphoma do not.
The brand is intentionally disease-agnostic. We're starting with T-cell lymphoma and plan to expand to other rare cancers over time.
Built by a clinician, for patients
Adit Singhal, MD, MS
Hematology/Oncology Fellow Physician · Northwell Health Cancer Institute
Patients with rare cancers face a challenge that is rarely discussed: finding clinical trials that are actually relevant to their diagnosis. For common cancers, dedicated trial-matching services and patient navigation tools exist. For T-cell lymphoma - a group of rare, aggressive blood cancers with over a dozen distinct subtypes - these resources simply do not.
ClinicalTrials.gov lists hundreds of trials that mention T-cell lymphoma, but fewer than 200 are truly applicable, and the database was never designed to help patients or community oncologists distinguish between them. The result is a significant information gap at a moment when patients and their families need clarity most.
I created TrialCompass to bridge that gap. Each trial is reviewed by a specialist, categorized by subtype and disease stage, and summarized in plain language - so that every patient, regardless of where they receive care, has access to the same quality of information.
Why this matters
Less than 5%
of adult cancer patients enroll in clinical trials — many never learn about options that could help them
70%
of patients say they would consider a clinical trial, but most are never informed of one by their physician
20–40%
Five-year survival for most PTCL subtypes — clinical trials offer access to promising new treatments
12+
Distinct T-cell lymphoma subtypes, each requiring different treatment approaches
The data says T-cell lymphoma is rare. For each person diagnosed, that statistic becomes their whole world. Better navigation tools can mean the difference between a missed trial and a found one — and sometimes, that's everything.
How trials are curated
Trial information is pulled from ClinicalTrials.gov and reviewed by hematology/oncology specialists. Each trial is classified by subtype and disease status, assigned a clinical priority, and given a plain-language summary written at an 8th-grade reading level. The database is refreshed monthly.
Understanding trial phases
- Phase 1 — Tests safety and dosing in a small group of people for the first time.
- Phase 2 — Tests whether the treatment actually works in a larger group.
- Phase 3 — Compares the new treatment against the current standard. These are usually the largest, most rigorous trials and can change practice.
Understanding our priority ratings
We assign each trial a clinical priority (1–5) to help you focus on what's most likely to matter.
- 1 — Highest: Landmark, practice-changing trials.
- 2 — High: Strong clinical rationale.
- 3 — Moderate: Reasonable options worth discussing.
- 4 — Lower: Early-stage or limited access.
- 5 — Exploratory: Very early or niche.
Important disclaimer
TrialCompass is for informational purposes only and is not medical advice. Always discuss clinical trial options with your healthcare team. Final eligibility for any trial is determined by the trial investigators based on a full medical evaluation.
Contact & feedback
Spot an error? Want to suggest a trial? Share your feedback.
Data last updated: June 2026